Acro Biomedical Co. Ltd. engages in the business of developing and marketing nutritional products that promote wellness and a healthy lifestyle. The company is headquartered in Fishers, Indiana. The company went IPO on 2016-06-23. The firm is focused on developing and marketing nutritional products that promote wellness and a healthy lifestyle. The firm's business consists of selling cordyceps related products that is used in traditional Chinese medicine. Cordyceps is a fungus which is a combination of a caterpillar and a fungus, which is found at altitudes above 4500 meters (m) in Sikkim. The firm is engaged in the purchase of products from three suppliers in Taiwan and the sale of these products to four unrelated customers. The company sells products in bulk to companies who may use the Company's products as ingredients in their products or sell the products they purchase from the Company to their own customers.
最新の財務諸表(Form-10K)によると、ACRO Biomedical Co Ltdの総資産は$0で、純損失は$0です。
ACBMの主要な財務比率は何ですか?
ACRO Biomedical Co Ltdの流動比率は0、純利益率は0、1株当たり売上高は$0です。
ACRO Biomedical Co Ltdの収益はセグメントまたは地域別にどのように分けられていますか?
ACRO Biomedical Co Ltd の最大収益セグメントは Vision Care で、最新の利益発表における収益は 2,923,000,000 です。地域別に見ると、U.S. and Puerto Rico が ACRO Biomedical Co Ltd の主要市場であり、収益は 2,546,000,000 です。